---
title: "Huahaipharm: Two products have obtained drug registration certificates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257506650.md"
description: "Huahaipharm recently obtained two drug registration certificates approved by the National Medical Products Administration, including Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Injection of Rosuvastatin Acetate. The approval for the production of these two products can be regarded as passing the consistency evaluation, further enriching the company's product line, enhancing market competitiveness, and having a positive impact on the company's operational development"
datetime: "2025-09-16T09:16:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257506650.md)
  - [en](https://longbridge.com/en/news/257506650.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257506650.md)
---

# Huahaipharm: Two products have obtained drug registration certificates

According to the Zhitong Finance APP, Huahai Pharmaceutical (600521.SH) announced that it recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (referred to as "NMPA") for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Injectable Ranitidine Hydrochloride Acetate.

According to relevant national policies, the company's Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Injectable Ranitidine Hydrochloride Acetate are approved for production as Class 3 chemical drugs, which can be regarded as passing the consistency evaluation. The acquisition of the "Drug Registration Certificate" from the NMPA for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Injectable Ranitidine Hydrochloride Acetate further enriches the company's product line, helps enhance the market competitiveness of the company's products, and has a positive impact on the company's operational development

### Related Stocks

- [600521.CN](https://longbridge.com/en/quote/600521.CN.md)

## Related News & Research

- [Barnes & Noble CEO is fine with stocking AI-written books — if they're labeled. The internet had thoughts.](https://longbridge.com/en/news/287084103.md)
- [Investeringsforeningen Nykredit Invest Balance suspender handel med udvalgte afdelinger](https://longbridge.com/en/news/286877547.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [ZAWYA: KIB Group, represented by KIB Invest, acts as Joint Lead Manager in landmark $700mln Sukuk issuance by First Abu Dhabi Bank](https://longbridge.com/en/news/287054139.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)